HYPERBARIC OXYGEN THERAPY

Gastroenterology

At Scottsdale Hyperbaric Center, Hyperbaric Oxygen Therapy (HBOT) is available as a supportive treatment for gastroenterological conditions, particularly those resulting from radiation therapy and chronic inflammation. HBOT has been shown to promote healing in patients suffering from radiation-induced enteritis, inflammatory bowel disease (IBD), and other gastrointestinal disorders by reducing inflammation, enhancing oxygen delivery to damaged tissues, and supporting overall gut health.

How Radiation Therapy Affects the Gastrointestinal System

Radiation therapy is a common treatment for cancers affecting the gastrointestinal (GI) tract, including colorectal, anal, stomach, pancreatic, and liver cancers. While effective, radiation can cause long-term side effects that impact the digestive system and overall gut health. Many patients experience conditions such as:

  • Radiation Enteritis: Inflammation of the small intestine leading to diarrhea, nausea, and abdominal pain.
  • Radiation Proctitis: Damage to the rectum, causing pain, bleeding, and bowel urgency.
  • Radiation Colitis: Inflammation and ulceration of the colon, resulting in chronic diarrhea and discomfort.
  • Chronic Abdominal Pain: Persistent pain due to nerve and tissue damage from radiation.
  • Malabsorption & Nutritional Deficiencies: Damage to the intestines that impairs nutrient absorption.
  • Fistulas & Non-Healing Ulcers: Formation of abnormal connections between the GI tract and other organs, leading to infections and complications.

These symptoms, collectively known as radiation-induced gastrointestinal injury, can arise months or even years after radiation therapy. Chronic inflammation, scarring, and reduced blood flow to the intestines contribute to long-term digestive issues, significantly impacting a patient’s quality of life.

How Hyperbaric Oxygen Therapy (HBOT) Supports Gastrointestinal Healing

Hyperbaric Oxygen Therapy (HBOT) has been shown to help patients suffering from radiation-induced GI injuries by:

  • Reducing Inflammation: HBOT decreases swelling and inflammation in the intestines, improving comfort and bowel function.
  • Promoting Angiogenesis (New Blood Vessel Growth): Increases oxygen supply to damaged tissues, enhancing healing and reducing scarring.
  • Enhancing Tissue Repair: Stimulates the production of collagen and stem cells, accelerating the repair of radiation-damaged intestines.
  • Supporting Microbiome Balance: May aid in restoring gut flora affected by radiation therapy and chronic inflammation.
  • Preventing Complications: Helps reduce the risk of ulceration, perforation, and infections related to radiation injury.

Gastroenterology-related conditions that may benefit from Hyperbaric Oxygen Therapy (HBOT) include:

Radiation-Induced Conditions:

  • Radiation Enteritis – Inflammation of the small intestine due to radiation therapy.
  • Radiation Proctitis – Damage to the rectum from pelvic radiation therapy.
  • Radiation Colitis – Inflammation and ulceration of the colon after radiation treatment.

Inflammatory & Autoimmune Conditions:

  • Crohn’s Disease – Chronic inflammatory bowel disease (IBD) that affects the digestive tract.
  • Ulcerative Colitis – Chronic inflammation and ulcers in the colon and rectum.
  • Microscopic Colitis – A form of colitis that causes chronic diarrhea.
  • Diverticulitis – Infection or inflammation of small pouches in the colon (diverticula).

Ischemic & Vascular Conditions:

  • Mesenteric Ischemia – Reduced blood flow to the intestines, leading to tissue damage.
  • Ischemic Colitis – Lack of blood flow to the colon causing inflammation and injury.

Post-Surgical & Chronic Wound Healing:

  • Anastomotic Leak – Leakage from surgical connections in the GI tract.
  • Fistulas – Abnormal connections between the intestines and other organs.
  • Non-Healing Ulcers – GI ulcers that do not heal due to poor oxygenation or chronic inflammation.

Infections & Gut Dysbiosis:

  • Clostridium difficile (C. diff) Infection – Severe gut infection causing colitis.
  • Small Intestinal Bacterial Overgrowth (SIBO) – Overgrowth of bacteria in the small intestine.
  • Gastric Ulcers (H. pylori-related) – Chronic ulcers in the stomach.

Post-Chemotherapy & Digestive Recovery:

  • Mucositis – Inflammation of the GI lining due to chemotherapy.
  • Gastritis – Stomach inflammation caused by infections, medications, or autoimmune conditions.
  • Pancreatitis – Inflammation of the pancreas.

HBOT can help by increasing oxygen delivery to damaged tissues, reducing inflammation, and promoting angiogenesis (new blood vessel formation), supporting recovery in many of these conditions.

Refer A Patient

  • Please submit the completed referral form along with supporting medical chart notes via fax to 480-590-6145.
  • For assistance with insurance coverage verification, our experienced team and insurance specialist, Isaac, is available to help determine if your patient qualifies for coverage.
  • Call our office today at 480-590-5277 to get started.

We look forward to working with you!

Read More

"Adjunctive Hyperbaric Oxygen Therapy in Refractory Crohn’s Disease: An Observational Study"

A study published in Oxidative Medicine and Cellular Longevity highlights the potential of Hyperbaric Oxygen Therapy (HBOT) in treating radiation-induced gastrointestinal injuries. The research demonstrates that HBOT significantly reduces inflammation, promotes tissue repair, and enhances recovery in patients suffering from conditions such as radiation enteritis and proctitis. These findings support HBOT’s growing role as an effective adjunctive treatment for managing gastrointestinal complications resulting from radiation therapy. (Source: Wiley Online Library (DOI: 10.1155/2021/6628142)
Read More
Read More

"Hyperbaric oxygen treatment of chronic refractory radiation proctitis: a randomized and controlled double-blind crossover trial with long-term follow-up"

This study assessed the effectiveness of hyperbaric oxygen therapy (HBOT) for chronic refractory radiation proctitis in cancer patients. A randomized, double-blind trial with crossover design included 150 patients, comparing HBOT (2.0 ATA) with a sham treatment (1.1 ATA). Results showed significant improvement in SOMA-LENT scores for the HBOT group, with a greater response rate (88.9%) compared to the control group (62.5%). The study concluded HBOT was effective in managing radiation-induced injury, particularly for late-stage proctitis. (Source: https://pubmed.ncbi.nlm.nih.gov/18342453/)
Read More
Read More

"Treatment of gastrointestinal radiation injury with hyperbaric oxygen"

This study explored the use of hyperbaric oxygen therapy (HBOT) in managing non-healing diabetic foot ulcers. The randomized controlled trial demonstrated that HBOT significantly improved healing rates compared to standard treatment. Patients receiving HBOT showed faster wound closure and reduced infection risks. The research supports HBOT as a promising adjunctive treatment for chronic wounds, especially in diabetic patients. (Source: https://pubmed.ncbi.nlm.nih.gov/17393937/)
Read More
Read More

"Hyperbaric oxygen treatment for inflammatory bowel disease: a systematic review and analysis"

This study examines the role of hyperbaric oxygen therapy (HBOT) in promoting wound healing, particularly in patients with chronic ulcers and other difficult-to-treat conditions. The findings suggest that HBOT can significantly enhance tissue repair by improving oxygen delivery to damaged areas, stimulating growth factors, and enhancing immune function. The research supports the use of HBOT as a supplementary treatment for various types of chronic wounds. (Source: Rossignol DA. Hyperbaric oxygen treatment for inflammatory bowel disease: a systematic review and analysis. Med Gas Res. 2012 Mar 15;2(1):6. doi: 10.1186/2045-9912-2-6. PMID: 22417628; PMCID: PMC3328239. https://pmc.ncbi.nlm.nih.gov/articles/PMC3328239/)
Read More
Read More

"Hyperbaric oxygen treatment of hemorrhagic radiation-induced gastritis after esophagectomy"

This study presents two cases of hemorrhagic radiation-induced gastritis following esophagectomy for esophageal cancer. The condition, believed to be caused by radiation damage, was successfully treated with hyperbaric oxygen therapy (HBOT), which rapidly stopped the bleeding. This is the first reported use of HBOT for this condition, suggesting its potential as an effective treatment for radiation-induced gastric injuries. (Source: Kernstine KH, Greensmith JE, Johlin FC, Funk GF, De Armond DT, Van Natta TL, Berg DJ. Hyperbaric oxygen treatment of hemorrhagic radiation-induced gastritis after esophagectomy. Ann Thorac Surg. 2005 Sep;80(3):1115-7. doi: 10.1016/j.athoracsur.2004.02.102. PMID: 16122506.)
Read More
Read More

"[Hyperbaric oxygen in the treatment of perineal Crohn's disease era of infliximab: a renewal interest?]"

This study reviews the potential of hyperbaric oxygen therapy (HBOT) in treating refractory perineal Crohn’s disease, particularly in the era of infliximab. A literature analysis found that HBOT showed a 68.18% remission rate in 22 patients across four key studies, comparable to infliximab’s 66% success rate. The authors suggest that combining HBOT with biotherapy may enhance healing and reduce recurrence. Further randomized controlled trials are needed to validate these findings. (Source: Bedioui H, Makni A, Magherbi H, Ben Safta Z. L'oxygénothérapie hyperbare dans le traitement de la maladie de Crohn perineale a l’ère de l’Infliximab : un regain d'intérêt ? [Hyperbaric oxygen in the treatment of perineal Crohn's disease era of infliximab: a renewal interest?]. Tunis Med. 2012 Jun;90(6):427-30. French. PMID: 22693080.)
Read More
Read More

"Hyperbaric oxygen treatment for inflammatory bowel disease: a systematic review and analysis"

This systematic review analyzed hyperbaric oxygen therapy (HBOT) for inflammatory bowel disease (IBD), including Crohn’s disease and ulcerative colitis. The study found that HBOT significantly reduced inflammation and oxidative stress markers in both human and animal studies. Patients with severe, treatment-resistant IBD showed high response rates, with minimal adverse effects. While results are promising, limitations such as small sample sizes and lack of control groups highlight the need for further research. (Source: https://pubmed.ncbi.nlm.nih.gov/22417628/.)
Read More